Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Jan 29 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David S. who wrote (799)	10/29/1998 5:15:00 PM
From: jopawa	of 965

I saw this on the wires. Obviously it accounts for the action today. Centocor says mature ReoPro sales may hit $2.2bln NEW YORK, Oct 29 (Reuters) - Biotech company Centocor Inc. (Nasdaq:CNTO - news) on Thursday said its heart medication ReoPro could ultimately generate annual sales of $2.2 billion and that its anti-inflammatory drug Remicade could be headed for annual sales of $1.2 billion. Centocor officials declined to say when the prescription drugs would hit those sales targets, but said they reflected their mature market potential. If it's accurate, were talking about a potential explosion in the price of CNTO. AMGN just reported Epogen sales of 350 mil for the qtr, anualized is 1.4 bil. Neupogen came in at 287 mil for the qtr, anualized is 1.2 bil. Combined sales roughly 2.6 bil for those two blockbusters. CNTO officials are talking about sales of 3.4 bil when sales reach maturity. Unless they are blowing smoke, you could easily see a 5-7 fold increase in the price of the shares if you compare CNTO to AMGN. John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next